Shares of EXACT Sciences Co. (NASDAQ:EXAS) gapped down before the market opened on Tuesday . The stock had previously closed at $84.81, but opened at $90.16. EXACT Sciences shares last traded at $92.35, with a volume of 2,533,302 shares changing hands.

EXAS has been the subject of several recent analyst reports. Benchmark upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a report on Monday, September 23rd. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Friday, January 10th. Canaccord Genuity decreased their price objective on shares of EXACT Sciences from $135.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. Leerink Swann lowered their price objective on shares of EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Finally, Citigroup began coverage on shares of EXACT Sciences in a research note on Monday, January 6th. They set a “buy” rating and a $120.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $122.06.

The company has a debt-to-equity ratio of 0.67, a current ratio of 2.75 and a quick ratio of 2.63. The company has a fifty day moving average of $91.53 and a 200-day moving average of $101.10. The firm has a market capitalization of $12.07 billion, a PE ratio of -65.95 and a beta of 1.35.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Tuesday, October 29th. The medical research company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. The firm had revenue of $218.81 million for the quarter, compared to the consensus estimate of $216.14 million. During the same quarter in the previous year, the company posted ($0.37) earnings per share. The business’s quarterly revenue was up 85.0% compared to the same quarter last year. Equities analysts anticipate that EXACT Sciences Co. will post -1.63 EPS for the current year.

In related news, insider G Bradley Cole sold 28,016 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $80.38, for a total transaction of $2,251,926.08. Following the transaction, the insider now owns 30,987 shares of the company’s stock, valued at $2,490,735.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of EXAS. Sheaff Brock Investment Advisors LLC lifted its holdings in EXACT Sciences by 1.8% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 6,900 shares of the medical research company’s stock worth $624,000 after purchasing an additional 125 shares during the last quarter. Shine Investment Advisory Services Inc. raised its position in shares of EXACT Sciences by 31.8% in the third quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 125 shares during the period. Strs Ohio raised its position in shares of EXACT Sciences by 0.3% in the third quarter. Strs Ohio now owns 66,784 shares of the medical research company’s stock valued at $6,035,000 after purchasing an additional 200 shares during the period. Kovack Advisors Inc. lifted its stake in shares of EXACT Sciences by 10.4% in the third quarter. Kovack Advisors Inc. now owns 2,485 shares of the medical research company’s stock worth $225,000 after buying an additional 235 shares during the last quarter. Finally, Coastal Investment Advisors Inc. lifted its stake in shares of EXACT Sciences by 65.7% in the third quarter. Coastal Investment Advisors Inc. now owns 648 shares of the medical research company’s stock worth $59,000 after buying an additional 257 shares during the last quarter. Institutional investors own 86.59% of the company’s stock.

About EXACT Sciences (NASDAQ:EXAS)

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: What are economic reports?

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.